High risk HPV16E6 stimulates hADA3 degradation by enhancing its SUMOylation

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages 1830-1839

  Chand, Vaibhav ^a   John, Rince ^a   Jaiswal, Neha ^a   Johar, Sumreet ^a   Nag, Alo ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Cervical cancer; Human papilloma virus; Proteasome degradation; SUMOylation; Ubiqutination

Indexed keywords

HADA3 PROTEIN; PROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN UBC9; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; TADA3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROCESSING; SUMOYLATION; UBIQUITINATION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; IMMUNOPRECIPITATION; METABOLISM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; TUMOR CELL CULTURE; UTERINE CERVIX TUMOR; VIROLOGY; WESTERN BLOTTING; WOUND HEALING;

BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOPRECIPITATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROTEOLYSIS; REPRESSOR PROTEINS; RISK FACTORS; SUMOYLATION; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; UBIQUITINATION; UTERINE CERVICAL NEOPLASMS; WOUND HEALING;

EID: 84905675336     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu104     Document Type: Article

References (41)

1. Doorbar, J. (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci, 110, 525-41.
2. Munger, K., et al. (2002) Human papillomavirus immortalization and transformation functions. Virus Res, 89, 213-28.
3. Zur Hausen, H. (2008) Papillomaviruses--to vaccination and beyond. Biochemistry, 73, 498-503.
4. Moody, C.A., et al. (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer, 10, 550-60.
5. Scheffner, M., et al. (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75, 495-505.
6. Munger, K., et al. (1989) Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J, 8, 4099-105.
7. Dyson, N., et al. (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-7.
8. Munger, K., et al. (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol, 63, 4417-21.
9. Werness, B.A., et al. (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248, 76-9.
10. Boyer, S.N., et al. (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res, 56, 4620-4.
11. Reznikoff, C.A., et al. (1996) Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res, 56, 2886-90.
12. Veldman, T., et al. (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci U S A, 100, 8211-6.
13. Kumar, A., et al. (2002) Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol, 22, 5801-12.
14. Nag, A., et al. (2007) An essential role of human Ada3 in p53 acetylation. J Biol Chem, 282, 8812-20.
15. Sekaric, P., et al. (2007) hAda3 regulates p14ARF-induced p53 acetylation and senescence. Oncogene, 26, 6261-8.
16. Shamanin, V.A., et al. (2008) hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. J Virol, 82, 3912-20.
17. Mohibi, S., et al. (2012) Mammalian alteration/deficiency in activation 3 (Ada3) is essential for embryonic development and cell cycle progression. J Biol Chem, 287, 29442-56.
18. Zeng, M., et al. (2002) Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J Biol Chem, 277, 45611-8.
19. Meng, G., et al. (2004) Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. J Biol Chem, 279, 54230-40.
20. Ogryzko, V.V., et al. (1998) Histone-like TAFs within the PCAF histone acetylase complex. Cell, 94, 35-44.
21. Wang, T., et al. (2001) hADA3 is required for p53 activity. EMBO J, 20, 6404-13.
22. Martinez, E., et al. (2001) Human STAGA complex is a chromatin-acetylating transcription coactivator that interacts with pre-mRNA splicing and DNA damagebinding factors in vivo. Mol Cell Biol, 21, 6782-95.
23. Germaniuk-Kurowska, A., et al. (2007) Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation. Cancer Res, 67, 11789-97.
24. Nag, A., et al. (2001) DDB2 induces nuclear accumulation of the hepatitis B virus X protein independently of binding to DDB1. J Virol, 75, 10383-92.
25. Leng, R.P., et al. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell, 112, 779-91.
26. Berns, K., et al. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 428, 431-7.
27. Yokota, K., et al. (2007) Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem, 282, 1998-2010.
28. Kuhne, C., et al. (1998) E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem, 273, 34302-9.
29. Gao, Q., et al. (2002) Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res, 62, 3315-21.
30. Nakagawa, S., et al. (2000) Human scribble (Vartul) is targeted for ubiquitinmediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol, 20, 8244-53.
31. Hu, Y., et al. (2009) HPV16 E6-induced and E6AP-dependent inhibition of the transcriptional coactivator hADA3 in human cervical carcinoma cells. Cancer Invest, 27, 298-306.
32. Geiss-Friedlander, R., et al. (2007) Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol, 8, 947-56.
33. Shuai, K. (2006) Regulation of cytokine signaling pathways by PIAS proteins. Cell Res, 16, 196-202.
34. Klug, H., et al. (2013) Ubc9 Sumoylation Controls SUMO Chain Formation and Meiotic Synapsis in Saccharomyces cerevisiae. Mol Cell, 50, 625-636.
35. Drag, M., et al. (2008) DeSUMOylating enzymes--SENPs. IUBMB Life, 60, 734-42.
36. Everett, R.D., et al. (2006) PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol, 80, 7995-8005.
37. Tatham, M.H., et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol, 10, 538-46.
38. Cheng, J., et al. (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell, 131, 584-95.
39. Thomas, M., et al. (1998) Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene, 17, 2943-54.
40. John, R., et al. (2011) Genotoxic stress induced posttranslational modification of transcriptional adaptor protein Ada3. J Proteins Proteom, 2, 71-79.
41. Wilson, V.G. (2012) Sumoylation at the host-pathogen interface. Biomolecules, 2, 203-227.